Cadila Pharmaceuticals’ journey has been marked by several milestones, including the development of indigenous formulations, expansion into global markets, and the creation of robust manufacturing and R&D capabilities
Vasograin Plus represents a major advancement in the treatment of migraine
A triple-action Formula for comprehensive respiratory relief
Allam was serving recently as the CEO at Public Investment Fund
The company will set-up a pharmaceuticals formulation manufacturing unit with an investment of Rs. 100 crore in Odisha
A seasoned professional, he will lead the strategy and business operations of Cadila’s branded prescriptions pharma business
The new single-pill therapy combines cilnidipine, telmisartan and metoprolol, bringing together three established antihypertensive agents with complementary mechanisms
Cadila Pharmaceuticals has introduced Dlorfast-M-Tablets as a dual-action therapy that targets two key pathways of allergic response
Subscribe To Our Newsletter & Stay Updated
